

Retrospective real-world study using machine learning to predict anemia events prior to talazoparib dose modification

First published: 26/10/2026

Last updated: 26/10/2026

Study

Planned

Administrative details

EU PAS number

EUPAS1000001108

Study ID

1000001108

DARWIN EU® study

No

Study countries



United States

Study status

Planned

Research institutions and networks

Institutions

Pfizer

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

Chenan Zhang chenan.zhang@pfizer.com

Study contact

chenan.zhang@pfizer.com

Primary lead investigator

Chenan Zhang

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 30/09/2024

Actual: 30/09/2024

Study start date

Planned: 10/11/2026

Data analysis start date

Planned: 10/11/2026

Date of final study report

Planned: 31/03/2028

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable

Methodological aspects

Study type

Study type list

Study type:

Non-interventional study

Study drug and medical condition

Medicinal product name, other

Talazoparib

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No